Embecta Corp.
EMBC · Surgical & Medical Instruments & Apparatus · 59.3M shares · +0%/yr ↑ shares · EDGAR filings ↗
Reference price $10.60 · est. market cap ~$629M — last insider purchase, 2025-05-23 (estimated from the dated SEC Form 4 price × shares outstanding — not a live quote)
Grade
B72Diabetes-care device company (insulin delivery, BD spinoff) — profitable with strong free cash flow; negative equity reflects spinoff leverage.
Strengths
- Profitable with strong FCF — operating margin 22% (95th), net margin 9% (81st), FCF $182M (89th), FCF margin 17%
Risks
- Negative equity from spinoff debt — D/E artifact
- Mature-market/competition risk — per 10-K
- Pen-needle commoditization risk — per 10-K
Notable findings
- Negative equityNegative book equity (debt/equity -2.13)
- Fund exitedNotable fund(s) exited this quarter: VANGUARD GROUP INC
- Strong balance sheetStrong balance sheet — $226M cash & investments
- Revenue declineRevenue -15.1% YoY
- Notable holderHeld by 5 notable fund(s): STATE STREET CORP, GOLDMAN SACHS GROUP INC, CITADEL ADVISORS LLC +2 more (as of 2026-03-31)
Quarterly revenue
Last 4 quarters · from SEC filings.
Key metrics
Gross margin
62.6%
Operating margin
22.4%
Net margin
8.8%
Return on equity
-14.7%
Return on assets
8.7%
ROIC
25.9%
Revenue growth (QoQ)
-15.1%
Net-income growth
21.8%
Debt / equity
-2.1×
Net debt / EBITDA
4.1×
Current ratio
2.4×
Free cash flow
$182M
EBITDA
$283M
Tangible book value
-$673M
Cash & investments
$226M
Stock comp / revenue
2.9%
Insider transactions · last 18 months
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-06-01 | Roth Anthony M. | Grant | 30K | — |
| 2026-02-11 | Pomeroy Claire | Grant | 23K | — |
| 2026-02-11 | Reidy Christopher R | Grant | 23K | — |
| 2026-02-11 | Prange Karen | Grant | 23K | — |
| 2026-02-11 | Anderson Carrie L | Grant | 23K | — |
| 2026-02-11 | HOMBACH ROBERT J. | Grant | 23K | — |
| 2026-02-11 | Morris Milton Mayo | Grant | 23K | — |
| 2025-11-26 | Mann Jeffrey Z | Tax withheld | 20K | $12.57 |
| 2025-11-26 | Kurdikar Devdatt | Grant | 288K | — |
| 2025-11-26 | Kurdikar Devdatt | Grant | 104K | — |
| 2025-11-26 | Kurdikar Devdatt | Tax withheld | 129K | $12.57 |
| 2025-11-26 | Elguicze Jacob | Grant | 95K | — |
| 2025-11-26 | Elguicze Jacob | Grant | 30K | — |
| 2025-11-26 | Curtis Shaun | Grant | 38K | — |
| 2025-11-26 | Curtis Shaun | Grant | 11K | — |
| 2025-11-26 | Curtis Shaun | Tax withheld | 15K | $12.57 |
| 2025-11-26 | Elguicze Jacob | Tax withheld | 25K | $12.57 |
| 2025-11-26 | Roth Anthony M. | Grant | 33K | — |
| 2025-11-26 | Roth Anthony M. | Tax withheld | 1.9K | $12.57 |
| 2025-11-26 | Casner Jean | Grant | 39K | — |
| 2025-11-26 | Casner Jean | Tax withheld | 3.3K | $12.57 |
| 2025-11-26 | Mann Jeffrey Z | Grant | 80K | — |
| 2025-11-26 | Mann Jeffrey Z | Grant | 24K | — |
| 2025-08-09 | Casner Jean | Tax withheld | 916 | $12.28 |
| 2025-05-23 | Melcher David F | Buy | 10K | $10.60 |
| 2025-04-04 | Elguicze Jacob | Tax withheld | 4.9K | $12.00 |
| 2025-04-04 | Curtis Shaun | Tax withheld | 3.2K | $12.00 |
| 2025-04-04 | Mann Jeffrey Z | Tax withheld | 5.3K | $12.00 |
| 2025-04-04 | Kurdikar Devdatt | Tax withheld | 40K | $12.00 |
| 2025-02-25 | Melcher David F | Buy | 13K | $13.67 |
| 2025-02-13 | Morris Milton Mayo | Sell | 3.1K | $16.38 |
| 2025-02-12 | Morris Milton Mayo | Grant | 14K | — |
| 2025-02-12 | Albritton David | Grant | 14K | — |
| 2025-02-12 | Anderson Carrie L | Grant | 14K | — |
| 2025-02-12 | Prange Karen | Grant | 14K | — |
| 2025-02-12 | Reidy Christopher R | Grant | 14K | — |
| 2025-02-12 | Pomeroy Claire | Grant | 14K | — |
| 2025-02-12 | HOMBACH ROBERT J. | Grant | 14K | — |
| 2025-02-12 | Melcher David F | Grant | 17K | — |
All non-derivative Form 4 activity (SEC), newest first.
Clinical trials
| Trial | Title | Phase | Status | Primary completion |
|---|---|---|---|---|
| NCT06692153 ↗ | Embecta AID System in Adults With Type 2 Diabetes Type 2 Diabetes, Type 2 Diabetes Mellitus (T2DM) | NA | Withdrawn | 2026-03-01 |
Source: ClinicalTrials.gov (U.S. NIH) · active studies first.
Notable events (8-K)
| Date | Items | |
|---|---|---|
| 2026-05-15 | Acquisition/dispositionReg FDExhibits | filing ↗ |
| 2026-05-05 | ResultsExhibits | filing ↗ |
| 2026-03-20 | Material agreementReg FDExhibits | filing ↗ |
| 2026-02-13 | Shareholder vote | filing ↗ |
| 2026-02-05 | ResultsExhibits | filing ↗ |
| 2025-11-25 | ResultsExhibits | filing ↗ |
| 2025-11-17 | Exec/director changeExhibits | filing ↗ |
| 2025-08-08 | ResultsExhibits | filing ↗ |
Recent filings
| Form | Filed | Period | Accession |
|---|---|---|---|
| 8-K | 2026-05-15 | 2026-05-15 | 0000947871-26-000546 ↗ |
| 8-K | 2026-05-05 | 2026-05-05 | 0001872789-26-000014 ↗ |
| 10-Q | 2026-05-05 | 2026-03-31 | 0001872789-26-000017 ↗ |
| 8-K | 2026-03-20 | 2026-03-19 | 0000947871-26-000310 ↗ |
| 8-K | 2026-02-13 | 2026-02-11 | 0000947871-26-000153 ↗ |
| 8-K | 2026-02-05 | 2026-02-05 | 0001872789-26-000005 ↗ |
| 10-Q | 2026-02-05 | 2025-12-31 | 0001872789-26-000009 ↗ |
| 10-K | 2025-11-25 | 2025-09-30 | 0001872789-25-000036 ↗ |
| 8-K | 2025-11-25 | 2025-11-25 | 0001872789-25-000033 ↗ |
| 8-K | 2025-11-17 | 2025-11-17 | 0000947871-25-001028 ↗ |
| 8-K | 2025-08-08 | 2025-08-08 | 0001872789-25-000025 ↗ |
| 10-Q | 2025-08-08 | 2025-06-30 | 0001872789-25-000029 ↗ |